Page 20 - Recursion Pharmaceuticals News Today

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) Director Blake Borgeson sold 8,885 shares of the stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $6.32, for a total transaction of $56,153.20. Following the transaction, the director now directly owns 7,407,420 shares in the company, valued at […]

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) CFO Michael Secora sold 25,000 shares of the stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $6.32, for a total value of $158,000.00. Following the sale, the chief financial officer now directly owns 925,686 shares of the company’s […]

This stock spiked more than 10% Tuesday.

Recursion Pharmaceuticals (NASDAQ:RXRX – Free Report) had its price target cut by Needham & Company LLC from $17.00 to $15.00 in a research report sent to investors on Thursday morning, Benzinga reports. They currently have a buy rating on the stock. Separately, KeyCorp upped their price objective on shares of Recursion Pharmaceuticals from $12.00 to […]

We’re still in the initial stages of a massively disruptive artificial intelligence (AI) boom that's greatly impacting healthcare.

Wilmington, Delaware, United States, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global AI in drug discovery market is projected to flourish at a CAGR of 36.1% from 2023 to 2031. As per the

Entered into a collaboration with Tempus giving Recursion access to over 20 petabytes of multimodal oncology data for the purpose of training causal AI...

Nvidia has been spreading its AI windfall across numerous start-ups.

Its groundbreaking work is winning it some powerful fans, but it's still risky.

Pioneering businesses tend to carry big risks, but also the potential for big rewards.